Publications by authors named "Sandra Lord"

Claim this Profile
P
Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial.
Meggan Mackay, Catriona A Wagner, Ashley Pinckney, Jeffrey A Cohen, Zachary S Wallace, Sandra Lord

JCI Insight· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.
Meggan Mackay, Catriona A Wagner, Ashley Pinckney, Jeffrey A Cohen, Zachary S Wallace, Sandra Lord

medRxiv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.
Stephan Pribitzer, Colin O'Rourke, Alyssa Ylescupidez, Megan Smithmyer, Christine Bender, Sandra Lord

J Clin Endocrinol Metab· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OGTT Metrics Surpass Continuous Glucose Monitoring Data for T1D Prediction in Multiple-Autoantibody-Positive Individuals.
Alyssa Ylescupidez, Cate Speake, Susan L Pietropaolo, Darrell M Wilson, Andrea K Steck, Sandra Lord

J Clin Endocrinol Metab· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Testing a new platform to screen disease-modifying therapy in type 1 diabetes.
Sandra M Lord, Henry T Bahnson, Carla J Greenbaum, David R Liljenquist, John Virostko

PLoS One· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A standardized metric to enhance clinical trial design and outcome interpretation in type 1 diabetes.
Alyssa Ylescupidez, Henry T Bahnson, Colin O'Rourke, Sandra Lord, Cate Speake

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.
William E Russell, Brian N Bundy, Mark S Anderson, Laura A Cooney, Stephen E Gitelman, Sandra M Lord

Diabetes Care· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABCC8-Related Monogenic Diabetes Presenting Like Type 1 Diabetes in an Adolescent.
Alexandra E Grier, Janet B McGill, Sandra M Lord, Cate Speake, Carla Greenbaum

AACE Clin Case Rep· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Darrell M Wilson, Susan L Pietropaolo, Maria Acevedo-Calado, Shuai Huang, Destiny Anyaiwe, Sandra M Lord

Diabetes Care· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity.
Jillian R Jaycox, Carolina Lucas, Inci Yildirim, Yile Dai, Eric Y Wang, Sandra Lord

Nat Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis.
Colin O'Rourke, Alyssa Ylescupidez, Henry T Bahnson, Christine Bender, Cate Speake, Sandra Lord

J Clin Endocrinol Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recognition of mRNA Splice Variant and Secretory Granule Epitopes by CD4+ T Cells in Type 1 Diabetes.
Perrin Guyer, David Arribas-Layton, Anthony Manganaro, Cate Speake, Sandra Lord

Diabetes· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.
Mara Kinney, Lu You, Emily K Sims, Diane Wherrett, Desmond Schatz, Sandra Lord

J Endocr Soc· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6-targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function.
Cate Speake, Tania Habib, Katharina Lambert, Christian Hundhausen, Sandra Lord

JCI Insight· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes.
Allison J Greaney, Rachel T Eguia, Tyler N Starr, Khadija Khan, Nicholas Franko, Sandra M Lord

PLoS Pathog· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterising the age-dependent effects of risk factors on type 1 diabetes progression.
Michelle So, Colin O'Rourke, Alyssa Ylescupidez, Henry T Bahnson, Andrea K Steck, Sandra Lord

Diabetologia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting Edge: Effect of Disease-Modifying Therapies on SARS-CoV-2 Vaccine-Induced Immune Responses in Multiple Sclerosis Patients.
Yevgeniy Yuzefpolskiy, Peter Morawski, Mitch Fahning, Cate Speake, Sandra Lord

J Immunol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes.
Allison J Greaney, Rachel T Eguia, Tyler N Starr, Khadija Khan, Nicholas Franko, Sandra M Lord

bioRxiv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes.
Carla J Greenbaum, Elisavet Serti, Katharina Lambert, Lia J Weiner, Sai Kanaparthi, Sandra Lord

JCI Insight· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes.
Sandra Lord, Carla J Greenbaum

F1000Res· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice.
Carla Greenbaum, Dana VanBuecken, Sandra Lord

Drugs· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.
Carla Greenbaum, Sandra Lord, Dana VanBuecken

Curr Diab Rep· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stress Testing of an Artificial Pancreas System With Pizza and Exercise Leads to Improvements in the System's Fuzzy Logic Controller.
Richard Mauseth, Sandra M Lord, Irl B Hirsch, Robert C Kircher, Don P Matheson

J Diabetes Sci Technol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
Sandra Lord, Carla J Greenbaum

Pharmacol Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis